NeuroSense Therapeutics: Funding, Investors & Team (Sep 2026)
NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes: (1) StabiliC for the treatment of Parkinson's disease and (2) CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics has raised $15.2M across 5 funding rounds on record, the most recent an undisclosed round of $600k announced in Apr 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NeuroSense Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
NeuroSense Therapeutics Funding Rounds
NeuroSense Therapeutics raised $4.5M in an undisclosed round announced in Jun 2023.
10 months later, an undisclosed round of $4.5M was announced in Apr 2024.
4 months later, an undisclosed round of $600k was announced in Aug 2024.
4 months later, an undisclosed round of $5.0M was announced in Dec 2024.
1.3 years later, an undisclosed round of $600k was announced in Apr 2026.
NeuroSense Therapeutics Founders and Leadership Team
Contact details for the NeuroSense Therapeutics team: 3 of 3 have an email address on file.
Start 14-day free trial →NeuroSense Therapeutics Funding Compared to Other Biotechnology Startups
NeuroSense Therapeutics' latest round of $600k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NeuroSense Therapeutics in Biotechnology and Herzliya
Companies Similar to NeuroSense Therapeutics
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
NeuroSense Therapeutics Funding FAQs
What does NeuroSense Therapeutics do?
NeuroSense Therapeutics Ltd., is a clinical-stage biotechnology company, dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company's preclinical pipeline includes: (1) StabiliC for the treatment of Parkinson's disease and (2) CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
How much funding has NeuroSense Therapeutics raised?
NeuroSense Therapeutics has raised $15.2M across 5 rounds on record. The most recent is an undisclosed round of $600k announced in Apr 2026.
When did NeuroSense Therapeutics last raise funding?
NeuroSense Therapeutics' most recent funding round on record is an undisclosed round of $600k, announced in Apr 2026.
Who founded NeuroSense Therapeutics?
FundedIQ lists Alon Ben (Founder), Alon Ben Noon (Founder), Alon Ben-Noon (Founder) at NeuroSense Therapeutics.
Where is NeuroSense Therapeutics headquartered?
NeuroSense Therapeutics is based in Herzliya, Tel Aviv, Israel.
How many employees does NeuroSense Therapeutics have?
NeuroSense Therapeutics is in the 11-50 employee band.
How does NeuroSense Therapeutics' funding compare to other Biotechnology startups?
NeuroSense Therapeutics' latest round of $600k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's NeuroSense Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NeuroSense Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.